Of the M&A practice, clients say: "It knows the work inside out and backwards, and its experience combined with the firm’s deep bench strength is a formidable combination. No matter what unusual circumstance arises during the transaction, there is someone within the firm who has gone through it before. They communicate among themselves on a global basis seamlessly - a form of knowledge management that adds significant value."
— Legal 500 US (2010)
Covington’s multi-disciplinary approach to life sciences brings together a leading M&A practice with top-ranked specialist life sciences lawyers and adds value where it counts the most. We provide thorough, sophisticated and - we believe - unparalleled analysis of the agreements, regulatory issues and IP rights that are central to most M&A transactions in the life sciences industry.
Further, our M&A lawyers have considerable experience working across disciplines on dual-track transactions and advising on deals as they evolve from acquisitions or dispositions to arrangements that are more collaborative in nature. This ability to address efficiently and effectively the fluidity of transactions in the life sciences sector is one of our greatest strengths and distinguishing characteristics.
Members of our corporate team are a fundamental part of our multi-disciplinary life sciences group and share the same commitment to, and enthusiasm for, the sector as do others in our practice. Our dedicated life sciences M&A team regularly advises multinational innovator pharmaceutical companies, emerging and mid-market life sciences companies, and investors on acquisitions and disposals of entire companies, divisions, and discrete products and technologies.
Representative Matters
- Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals and in its $410 million acquisition of Evalve Inc.
- Boehringer Ingelheim in its acquisition of a significant portion of Wyeth’s Fort Dodge Animal Health business in certain countries in connection with Pfizer’s acquisition of Wyeth, including products in the US, Europe, Canada, Australia and South Africa as well as two manufacturing and research facilities.
- Forest Laboratories, Inc. in its $1.2 billion acquisition of Clinical Data, Inc., a specialty pharmaceuticals company.
- King Pharmaceuticals in its $3.6 billion merger with Pfizer.
- Medarex in its $2.4 billion merger with Bristol-Myers Squibb.
- Procter & Gamble in its $3.1 billion sale of its global pharmaceuticals business to Warner Chilcott; in its sale of ThermaCare, a leading over-the-counter heat wrap, to Wyeth Consumer Healthcare; and in its sale of its Noxema skin care brand in the US, Canada and certain portions of Latin America to Alberto-Culver Company.
- Salix Pharmaceuticals, Ltd. in its $300 million acquisition of Oceana Therapeutics, LLC.
- Gilead Sciences in its $120 million acquisition of CGI Pharmaceuticals.
- Intercell in its $189 million acquisition of Iomai and in its acquisition of Cytos Biotechnology Ltd.'s platform technology for monoclonal antibody discovery.
- Eli Lilly in its acquisition of SGX Pharmaceuticals and in the sale of its Tippecanoe manufacturing facility to Evonik Industries.
- Coty, Inc. in its sale of the Orajel brand and other brands of Del Pharmaceuticals to Church & Dwight.
- Itochu International, the North American subsidiary of ITOCHU, in its acquisition of medical specialty devices companies Products for Surgery Inc. and Flanagan Instruments, Inc., and in its acquisition of Life Systems and Instrumentation Corporation, a distributor of specialty surgical products.
- Thomson Healthcare in its sale of the American Health Consultants and BioWorld groups to the Thompson Publishing Group.
|
|